Recent advances of HIF-2α in pulmonary hypertension
10.16438/j.0513-4870.2021-0632
- VernacularTitle:HIF-2α在肺动脉高压中的研究进展
- Author:
Lei JI
1
,
2
,
3
;
Zhan-qiang LI
1
,
2
;
Dian-xiang LU
1
,
2
Author Information
1. Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China
2. Key Laboratory of High Altitude Medicine (Ministry of Education), Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Xining 810001, China
3. Qinghai Provincial People's Hospital, Xining 810007, China
- Publication Type:Research Article
- Keywords:
hypoxic inducible factor-2α;
pulmonary hypertension;
endothelial cell;
hypoxic inducible factor-1α;
treatment
- From:
Acta Pharmaceutica Sinica
2022;57(2):277-286
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension (PH) is a kind of disease characterized by progressive increase of pulmonary vascular resistance and occlusive vascular remodeling. Hypoxic inductive factor-2α (HIF-2α) plays an important role in the abnormal proliferation of pulmonary vascular cells and pulmonary vascular remodeling. This review focuses on the role of HIF-2α in pulmonary hypertension at the cellular and the global level, and candidates targeting HIF-2α for the treatment of pulmonary hypertension, in order to better understand the pathogenesis of PH and find effective treatments.
